Thermo Fisher Scientific Inc. (TMO) News
Track canonical SquawkNews coverage tagged to TMO, Thermo Fisher Scientific Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 23 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
$1000 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today
Thermo Fisher Scientific (NYSE: TMO ) has outperformed the market over the past 10 years by 1.15% on an annualized basis producing an average annual return of 14.61%. Currently, Thermo Fisher Scientific has a market capi
EQUITY | Aug 11, 2026, 08:00 PM UTC
H
Thermo Fisher Points to Improving End-Market Activity
Thermo Fisher Scientific Inc. (NYSE: TMO ) on Thursday reported second-quarter adjusted earnings of $6.03 per share, beating the street view of $5.71. The life science giant’s quarterly sales of $11.994 billion increased
EARNINGS | Jul 23, 2026, 07:07 PM UTC
L
DHR +5.6% at highs, bouncing off of Tuesday's sell off post lower guide, being helped by better results in Life Science/tools today TMO and
DHR +5.6% at highs, bouncing off of Tuesday's sell off post lower guide, being helped by better results in Life Science/tools today TMO and SOAGY Sartorius in Europe
EQUITY | Jul 23, 2026, 03:30 PM UTC
H
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index dipping around 450 points on Thursday. Shares of Lockheed Martin Corp (NYSE: LMT ) rose sharply after the company reported better-than-expected second-quarter financial re
EARNINGS | Jul 23, 2026, 02:20 PM UTC
L
TMO +10% after Q2 profit beat
TMO +10% after Q2 profit beat
EARNINGS | Jul 23, 2026, 01:34 PM UTC
H
Thermo Fisher Scientific Raises FY2026 Adj EPS Guidance from $24.64-$25.12 to $24.93-$25.33 vs $24.86 Est; Raises FY2026 Sales Guidance from
Thermo Fisher Scientific (NYSE: TMO ) raises FY2026 Adj EPS guidance from $24.64-$25.12 to $24.93-$25.33 vs $24.86 analyst estimate. Raises FY2026 sales outlook from $47.300 billion-$48.100 billion to $47.400 billion-$48
EARNINGS | Jul 23, 2026, 01:33 PM UTC
L
TMO thermo fisher exec notes academic and government returned to growth in Q2 but market going through stabilization, didn't change outlook
TMO thermo fisher exec notes academic and government returned to growth in Q2 but market going through stabilization, didn't change outlook for segment
RATES | Jul 23, 2026, 01:06 PM UTC
L
TMO Thermo Fisher Scientific exec notes good to see Biotech customer activity translating to revenue - conf call
TMO Thermo Fisher Scientific exec notes good to see Biotech customer activity translating to revenue - conf call
RATES | Jul 23, 2026, 01:04 PM UTC
L
TMO Thermo Fisher Scientific exec notes expect Q3 adj EPS to be 35 to 40 cents higher than in Q2 - conf call
TMO Thermo Fisher Scientific exec notes expect Q3 adj EPS to be 35 to 40 cents higher than in Q2 - conf call
RATES | Jul 23, 2026, 12:57 PM UTC
H
Intel Could Swing By $68.3 Billion After Earnings
Earnings are back in focus on Thursday, with a -selected watchlist that spans defense, wireless, life sciences, gold mining and semiconductors. With guidance and segment commentary often moving stocks as much as the head
RATES | Jul 23, 2026, 11:16 AM UTC
H
TMO Thermo Fisher RESULTS: Q2, Q2 EPS $4.68, Q2 REV $11.994B vs. EST $11.701B, Q2 ADJ EPS $6.03 vs. EST $5.71, Q2 ADJ Net Income $2.241B vs.
TMO Thermo Fisher RESULTS: Q2, Q2 EPS $4.68, Q2 REV $11.994B vs. EST $11.701B, Q2 ADJ EPS $6.03 vs. EST $5.71, Q2 ADJ Net Income $2.241B vs. EST $2.134B, Thermo Fisher Earnings Notes:, We are well positioned to deliver a
RATES | Jul 23, 2026, 10:30 AM UTC
L
Thermo Fisher reports Q2 adjusted EPS $6.03, consensus $5.71
Reports Q2 revenue...
EQUITY | Jul 23, 2026, 10:01 AM UTC
H
$TMO Thermo Fisher Scientific Q2 Earnings
$TMO Thermo Fisher Scientific Q2 Earnings
EARNINGS | Jul 23, 2026, 10:01 AM UTC
H
DHR -12% premarket after results, guidance; Peers A -3%, TMO -3%, RVTY, ILMN down about 2%
DHR -12% premarket after results, guidance; Peers A -3%, TMO -3%, RVTY, ILMN down about 2%
EARNINGS | Jul 21, 2026, 12:30 PM UTC
L
Near 200dma support DUK WMS EXC TMO GXO ATO HOOD DCI TJX META MAA XEL RCL COF CSL AGCO ZBH CMS CDNS EMN MSA BILL
Near 200dma support DUK WMS EXC TMO GXO ATO HOOD DCI TJX META MAA XEL RCL COF CSL AGCO ZBH CMS CDNS EMN MSA BILL
EQUITY | Jul 17, 2026, 04:41 PM UTC
L
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
EQUITY | Jul 15, 2026, 12:17 PM UTC
H
TMO DHR RGEN SOAGY Bioprocessing Names Likely to Deliver Most 'Leverage' in Tools This Earnings Season @ KEYB
TMO DHR RGEN SOAGY Bioprocessing Names Likely to Deliver Most 'Leverage' in Tools This Earnings Season @ KEYB
EARNINGS | Jul 15, 2026, 11:14 AM UTC
H
TMO MTD RVTY A GH Like names in Life Sciences into Q2 earnings for space @ Stifel
TMO MTD RVTY A GH Like names in Life Sciences into Q2 earnings for space @ Stifel
EARNINGS | Jul 14, 2026, 11:25 AM UTC
H
Thermo Fisher named short-term buy idea at Deutsche Bank
Deutsche Bank placed a "Catalyst call: Buy" on shares of Thermo Fisher as a short-term investment idea. The set-up for the stock entering Q2 earnings is improved with sentiment tilting more negatively due to investor con
EQUITY | Jul 09, 2026, 12:35 PM UTC
L
Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $570 From $575
() -- Thermo Fisher Scientific (TMO) has an average rating of overweight and mean price target of $595, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and resea
EQUITY | Jul 06, 2026, 12:56 PM UTC
H
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) is collaborating with Thermo Fisher Scientific Inc. (NYSE: TMO ) to support the Phase 3 development and potential commercialization of ARCT-032, the company’s investiga
MACRO | Jul 02, 2026, 03:32 PM UTC
L
Arcturus Therapeutics Collaborates With Thermo Fisher Scientific To Help Support Phase 3 Development And Potential Commercialization Of ARCT
Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights Arcturus Therapeutics Holdings Inc. (("Arcturus", NASDAQ: ARCT ), a messenger RNA medicines company focused on the de
EQUITY | Jul 02, 2026, 11:02 AM UTC
M
TMO: Bernstein Reinstates
Bernstein reinstates Thermo Fisher Scientific with a Market Perform rating and $520 price target
EQUITY | Jun 26, 2026, 01:16 PM UTC